Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis

Next Previous
Search
Trial Profile

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Prurigo nodularis
  • Focus Therapeutic Use
  • Acronyms TRuE-PN2
  • Sponsors Incyte Corporation

    • Most Recent Events

    • 08 Mar 2025 According to Incyte Corporation media release, the findings from the TRuE-PN1 and TRuE-PN2 studies will inform planned discussions with regulatory authorities to find out the next steps.
    • 08 Mar 2025 According to Incyte Corporation media release, data from this study will be submitted for presentation at an upcoming scientific meeting.
    • 08 Mar 2025 According to Incyte Corporation media release, topline data from the Phase 3 TRuE-PN2 clinical trial demonstrated a strong positive trend across all key secondary endpoints, while the primary endpoint did not reach statistical significance.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top